Qiagen (QGEN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
6 Nov, 2026Opening remarks and agenda
Roland Sackers chaired the meeting; Stephen H. Rusckowski, Jonathan Pratt, Kaspar Nuttigall and Christiana Williams attended in their stated roles.
Record date was October 9, 2026; 206,496,521 shares had voting rights, with 137,321,285 represented, equal to 66% of issued share capital.
Agenda items covered Thierry Bernard’s discharge, Jonathan Pratt’s appointment, and closure of the meeting.
Specific resolutions to be voted on
Discharge of Thierry Bernard from liability for Managing Board duties from January 1 to his resignation on September 1, 2026, was adopted.
Appointment of Jonathan Pratt as Managing Director, from the day after the meeting through the 2027 Annual General Meeting, was adopted.
Board and executive committee updates
Thierry Bernard resigned from the Managing Board effective September 1, 2026; the meeting voted on his discharge for duties performed through that date.
Jonathan Pratt was nominated as a new Managing Board member and appointed for a term ending at the 2027 Annual General Meeting.
Latest events from Qiagen
- Pillar-led Q3 growth met takeover uncertainty as 2026 guidance was suspended.QGEN
Q3 2026 - 8% CER non-COVID growth lifted Q4 results; 2024 earnings face non-operating headwinds.QGEN
Q4 2023 - AI-driven automation, new product launches, and margin expansion drive growth amid strategic review.QGEN
Morgan Stanley 24th Annual Global Healthcare Conference - Automation, new launches, and strategic focus drive growth outlook amid leadership transition.QGEN
2026 Global Healthcare Conference - Q2 2026 sales and EPS exceeded expectations, driven by strong growth in core pillars.QGEN
Q2 2026 - New product launches and strategic review drive growth amid leadership transition and stable funding.QGEN
Leerink Global Healthcare Conference 2026 - Q1 2026 delivered 2% sales growth and solid profitability, with FY 2026 outlook reaffirmed.QGEN
Q1 2026 - Drives growth in sample prep with automation, high-value applications, and new tech leadership.QGEN
Status Update - 2028 plan targets ~7% sales CAGR, ≥31% margin, and $1B returns, led by innovation and efficiency.QGEN
CMD 2024